Revolution Medicines Receives FDA Priority Voucher for Cancer Drug Daraxonrasib

Revolution Medicines awarded FDA National Priority Voucher for daraxonrasib (RMC-6236), a breakthrough RAS inhibitor targeting pancreatic and lung cancer in Phase 3 trials.